Minerva Neurosciences (NASDAQ:NERV – Free Report) had its price objective decreased by HC Wainwright from $11.00 to $7.00 in a research note published on Thursday morning, Benzinga reports. HC Wainwright currently has a neutral rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Minerva Neurosciences’ Q1 2025 earnings at ($1.03) EPS, Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.76) EPS and Q4 2025 earnings at ($0.92) EPS.
Separately, StockNews.com downgraded Minerva Neurosciences from a hold rating to a sell rating in a report on Friday, February 23rd.
Read Our Latest Report on Minerva Neurosciences
Minerva Neurosciences Stock Up 0.9 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last released its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.31). As a group, sell-side analysts anticipate that Minerva Neurosciences will post -3.57 earnings per share for the current fiscal year.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Featured Articles
- Five stocks we like better than Minerva Neurosciences
- How to Read Stock Charts for Beginners
- MarketBeat Week in Review – 4/29 – 5/3
- Profitably Trade Stocks at 52-Week Highs
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What is an Earnings Surprise?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.